



Pharmacy Request for Prior Approval – Sovaldi

Beneficiary Information

1. Beneficiary Last Name: \_\_\_\_\_ 2. First Name: \_\_\_\_\_
3. Beneficiary ID #: \_\_\_\_\_ 4. Beneficiary Date of Birth: \_\_\_\_\_ 5. Beneficiary Gender: \_\_\_\_\_

Prescriber Information

6. Prescriber Name: \_\_\_\_\_ NPI #: \_\_\_\_\_
Mailing address: \_\_\_\_\_ City: \_\_\_\_\_ State: \_\_\_\_\_ ZIP: \_\_\_\_\_
7. Requester Contact Information: \_\_\_\_\_
Name: \_\_\_\_\_ Phone #: \_\_\_\_\_ Fax #: \_\_\_\_\_

Drug Information

8. Drug Name: \_\_\_\_\_ 9. Strength: \_\_\_\_\_ 10. Quantity Per 28 Days: \_\_\_\_\_
11. Length of Therapy: \_\_\_12 weeks \_\_\_24 weeks \_\_\_48 weeks

Clinical Information

Total length of therapy being requested (Check ONE):
\_\_\_ 12 weeks = Genotype 1, 2, or 4 for treatment-naïve and treatment-experienced adult beneficiaries without cirrhosis or with compensated cirrhosis (child-pugh A); or genotype 2 for treatment-naïve and treatment-experienced pediatric patients, 3 years of age or older, without cirrhosis or with compensated cirrhosis (child-pugh A).
• Genotype 1 and previously treated with a regimen containing an NS3/4A PI2 without prior treatment with an NS5A inhibitor.
\_\_\_ 24 weeks = Genotype 1 adult beneficiaries that are PEG-interferon ineligible; genotype 3 for treatment-naïve and treatment experienced adults without cirrhosis or with compensated cirrhosis (child-pugh A); Or genotype 3 for treatment-naïve and treatment-experienced pediatric patients, 3 years of age or older, without cirrhosis or with compensated cirrhosis (child-pugh A).
\_\_\_ 48 weeks = Genotype 1,2,3, or 4 for adult beneficiaries with a diagnosis of Hepatocellular Carcinoma awaiting liver transplantation (up to 48 weeks or until liver transplantation, whichever comes first).
1. Does the beneficiary have a diagnosis of chronic hepatitis C infections with one of the following confirmed diagnosis':
\_\_\_ Genotype 1 or 4 without cirrhosis or with compensated cirrhosis and beneficiary is 18 years of age or older
\_\_\_ Genotype 2 or 3 without cirrhosis or with compensated cirrhosis and beneficiary is 3 years of age or older
\_\_\_ Beneficiary has CHC infection with hepatocellular carcinoma awaiting liver transplant
2. Are medical records documenting the diagnosis of chronic hepatitis C with genotype and subtype being submitted with this request?
Yes \_\_\_ No \_\_\_ \*\*Lab test results MUST be attached to the PA to be approved.\*\*
3. Does the beneficiary have a documented quantitative HCV RNA at baseline that was tested within the past 6 months (medical documentation required)? Yes \_\_\_ No \_\_\_ HCV RNA (IU/ml): \_\_\_\_\_ and/or log10 value: \_\_\_\_\_
4. As the provider, are you reasonably certain that treatment will improve the beneficiary's overall health status? Yes \_\_\_ No \_\_\_
5. Is Sovaldi being prescribed in combination with ribavirin and pegylated interferon alfa for genotypes 1 and 4? Yes \_\_\_ No \_\_\_
6. Is Sovaldi being prescribed in combination with ribavirin for beneficiaries with genotype 1 who are peginterferon-ineligible (medical record documentation of previous peginterferon therapy or reason for ineligibility must be submitted for review)? Yes \_\_\_ No \_\_\_
7. Is Sovaldi being prescribed in combination with ribavirin for genotypes 2 and 3 and/or in CHC beneficiaries with hepatocellular carcinoma awaiting liver transplant? Yes \_\_\_ No \_\_\_
8. Is Sovaldi being used as monotherapy? Yes \_\_\_ No \_\_\_
9. Is Sovaldi being used with any other sofosbuvir-containing regimen? Yes \_\_\_ No \_\_\_
10. Does the beneficiary have any FDA labeled contraindications to sofosbuvir (Sovaldi)? Yes \_\_\_ No \_\_\_
11. Is the Beneficiary pregnant? Yes \_\_\_ No \_\_\_
12. Does the beneficiary have severe renal impairment (CrCl less than 30 mL/min), end stage renal disease, or require dialysis (AASLD/IDSA 2014)? Yes \_\_\_ No \_\_\_
13. Is the beneficiary a non-responder to sofosbuvir? Yes \_\_\_ No \_\_\_
14. Has the beneficiary previously failed therapy with a treatment regimen that included sofosbuvir? Yes \_\_\_ No \_\_\_
15. Does the beneficiary have hepatocellular carcinoma and is not awaiting a liver transplant? Yes \_\_\_ No \_\_\_

Signature of Prescriber: \_\_\_\_\_

Date: \_\_\_\_\_

\*Prescriber signature mandatory

I certify that the information provided is accurate and complete to the best of my knowledge, and I understand that any falsification, omission, or concealment of material fact may subject me to civil or criminal liability.